Related Experiment Videos
Why screen for cystic fibrosis? A clinician's view
1Department of Child Health, Singleton Hospital, Swansea, Wales, UK. J.A.Dodge@btinternet.com
Acta Paediatrica (Oslo, Norway : 1992). Supplement
|January 8, 2000
Summary
Neonatal screening for cystic fibrosis (CF) identifies infants early, enabling prompt treatment to prevent lung damage and improve survival. Early diagnosis enhances the doctor-parent relationship and is supported by most CF professionals and parents.
Area of Science:
- Pediatrics
- Medical Genetics
- Public Health
Background:
- Cystic fibrosis (CF) is a serious genetic disorder causing progressive lung damage.
- Clinical diagnosis often occurs after irreversible lung damage has begun.
- Early-life infections are common in infants with CF.
Purpose of the Study:
- To highlight the benefits of neonatal screening for cystic fibrosis.
- To emphasize the importance of early intervention before lung damage is evident.
- To discuss the clinical, relational, and economic aspects of CF screening.
Main Methods:
- The abstract discusses the implications of a well-organized screening program.
- It reviews the benefits of active treatment for both screened and unscreened infants.
- It considers the anticipated impact of future treatments on early-diagnosed infants.
Main Results:
- Neonatal screening can identify most CF infants within three weeks of birth.
- Early treatment improves clinical status and long-term survival.
- Pre-symptomatic diagnosis improves the doctor-parent relationship.
- Screening is considered cost-beneficial to cost-neutral.
Conclusions:
- Neonatal screening for CF is crucial for timely preventive treatment and surveillance.
- Early diagnosis maximizes the benefit of current and future CF therapies.
- The majority of CF professionals and parents support neonatal screening programs.